PT944389E - Composições purificadas de 10-propargil-10-desaza-aminopterina e métodos para a sua utilização no tratamento de tumores - Google Patents

Composições purificadas de 10-propargil-10-desaza-aminopterina e métodos para a sua utilização no tratamento de tumores Download PDF

Info

Publication number
PT944389E
PT944389E PT97934905T PT97934905T PT944389E PT 944389 E PT944389 E PT 944389E PT 97934905 T PT97934905 T PT 97934905T PT 97934905 T PT97934905 T PT 97934905T PT 944389 E PT944389 E PT 944389E
Authority
PT
Portugal
Prior art keywords
propargyl
tumors
10dam
deazaaminopterin
treatment
Prior art date
Application number
PT97934905T
Other languages
English (en)
Inventor
Francis M Sirotnak
James R Piper
Joseph I Degraw
William T Colwell
Original Assignee
Sloan Kettering Inst Cancer
Stanford Res Inst Int
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21806781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT944389(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer, Stanford Res Inst Int, Southern Res Inst filed Critical Sloan Kettering Inst Cancer
Publication of PT944389E publication Critical patent/PT944389E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
PT97934905T 1996-07-17 1997-07-16 Composições purificadas de 10-propargil-10-desaza-aminopterina e métodos para a sua utilização no tratamento de tumores PT944389E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2190896P 1996-07-17 1996-07-17

Publications (1)

Publication Number Publication Date
PT944389E true PT944389E (pt) 2008-12-03

Family

ID=21806781

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97934905T PT944389E (pt) 1996-07-17 1997-07-16 Composições purificadas de 10-propargil-10-desaza-aminopterina e métodos para a sua utilização no tratamento de tumores

Country Status (10)

Country Link
US (1) US6028071A (pt)
EP (2) EP2258702A3 (pt)
JP (2) JP2001505537A (pt)
AT (1) ATE407677T1 (pt)
CA (1) CA2260266C (pt)
DE (1) DE69738981D1 (pt)
DK (1) DK0944389T3 (pt)
ES (1) ES2313737T3 (pt)
PT (1) PT944389E (pt)
WO (1) WO1998002163A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780808B1 (fr) * 1998-07-03 2001-08-10 Thomson Csf Dispositif a emission de champ et procedes de fabrication
US20040053836A1 (en) * 2002-04-22 2004-03-18 Philipp Mayer-Kuckuk Method for modulating the production of a selected protein in vivo
ZA200609266B (en) * 2004-05-30 2008-12-31 Sloan Kettering Inst Cancer Treatment of t-cell lymphoma using 10-propargyl-10-deaza-aminopterin
US8263354B2 (en) 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
US20080188479A1 (en) * 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
WO2011096947A1 (en) * 2010-02-02 2011-08-11 Allos Therapeutics, Inc. Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same
KR20130115993A (ko) * 2010-06-02 2013-10-22 알로스 쎄러퓨틱스, 아이엔씨. 10-프로파길-10-데아자아미노프테린을 이용하여 메토트렉세이트-내성 장애를 치료하는 방법
WO2012061469A2 (en) 2010-11-02 2012-05-10 Sicor Inc. Crystalline forms of pralatrexate
ES2575864T3 (es) 2011-12-21 2016-07-01 Teva Pharmaceuticals International Gmbh Procesos e intermedios para preparar pralatrexato
WO2013164856A1 (en) * 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
WO2013177713A1 (en) * 2012-05-31 2013-12-05 Alphora Research Inc. Process for preparation of an antifolate agent
WO2014016740A2 (en) 2012-07-23 2014-01-30 Fresenius Kabi Oncology Ltd. Improved process for the preparation of pralatrexate
WO2014020553A1 (en) 2012-08-03 2014-02-06 Fresenius Kabi Oncology Ltd. Salts of pralatrexate
US9783542B2 (en) * 2012-11-02 2017-10-10 Hetero Research Foundation Process for pralatrexate
WO2014187274A1 (zh) * 2013-05-24 2014-11-27 苏州明锐医药科技有限公司 普拉曲沙及其中间体的制备方法
CN103588775B (zh) * 2013-11-12 2016-08-17 连云港恒运医药科技有限公司 普拉曲沙降解杂质及其制备方法
AU2016277929B2 (en) 2015-06-16 2020-09-10 Acrotech Biopharma Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) * 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis

Also Published As

Publication number Publication date
CA2260266A1 (en) 1998-01-22
EP0944389A4 (en) 2001-04-04
DK0944389T3 (da) 2008-11-17
EP2258702A3 (en) 2011-11-30
EP2258702A2 (en) 2010-12-08
WO1998002163A1 (en) 1998-01-22
JP2009091361A (ja) 2009-04-30
JP2001505537A (ja) 2001-04-24
ES2313737T3 (es) 2009-03-01
DE69738981D1 (de) 2008-10-23
EP0944389B1 (en) 2008-09-10
US6028071A (en) 2000-02-22
ATE407677T1 (de) 2008-09-15
EP0944389A1 (en) 1999-09-29
JP5271677B2 (ja) 2013-08-21
CA2260266C (en) 2011-01-18

Similar Documents

Publication Publication Date Title
EP0944389A4 (en) PURIFIED COMPOSITIONS OF 10-PROPARGYL-10-DEAZAAMINOPTERIN AND METHODS OF USE THEREOF FOR THE TREATMENT OF TUMORS
GR3035117T3 (en) Use of mannose phosphates for the treatment of fibrotic disorders
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
IL136690A0 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
AU1808488A (en) Compounds for the treatment of alzheimer's disease
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
PL302304A1 (en) Peptides of body organs protecting action, method of obtaining them and their application in therapy
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
GR3034761T3 (en) Methods of enhancing wound healing and tissue repair.
EP0303681A4 (en) IMMUNOSUPPRESSION IN THE TREATMENT OF PEOPLE BASED ON IMMUNOTOXIN.
PT1076561E (pt) Terapia de combinacao para o tratamento de tumores
EP0588477A3 (en) Medicinal composition comprising tcf-ii
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
IL159770A0 (en) Calcium salts with cytotoxic activity
EP1351967A4 (en) COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
MX9802809A (es) Ureasa para el tratamiento de infecciones de helicobacter pylori.
DE3485282D1 (de) Zusammensetzung zur behandlung von boesartigen tumoren insbesondere bei tieren.
GB9625193D0 (en) Treatment of highly vascular tumours
KR0177821B1 (en) Pharmaceutical compositions containing 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans
WO1990011078A8 (en) Regional chemotherapy with 4-hydroperoxycyclophosphamide
AU4459897A (en) Use of cytokines and cytotoxic substances in a new method to treat tumors
RU93051939A (ru) Способ лечения опухолей полости рта